We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App





EKF Highlights Diagnostic Technologies for Point-of-Care Testing Applications

By LabMedica International staff writers
Posted on 13 Nov 2023
Print article
Image: EKF is showcasing its products and services at MEDICA 2023 at Hall 3, Stand B69 (Photo courtesy of EKF Diagnostics)
Image: EKF is showcasing its products and services at MEDICA 2023 at Hall 3, Stand B69 (Photo courtesy of EKF Diagnostics)

EKF Diagnostics (Cardiff, Wales, UK) is showcasing its diagnostic technologies and biotechnology solutions at MEDICA 2023 that empower healthcare and medical providers to make informed clinical decisions through point-of-care testing and life sciences applications.

EKF offers cutting-edge point-of-care diagnostic solutions that provide healthcare professionals and patients with rapid, accurate, and accessible testing capabilities and results. The company’s technologies allow for informed decision-making, timely interventions, and improved patient outcomes at the point of care. EKF leads in supporting life sciences applications and research through innovative biotechnology solutions. The company’s comprehensive portfolio offers powerful tools to researchers, scientists, and clinicians for accurate and reliable delivery and results, driving breakthrough discoveries and advancements in healthcare and medical understanding.

Visitors to the EKF booth can explore the company’s range of point-of-care medical diagnostic solutions for hematology and diabetes, including the DiaSpect Tm and Hemo Control hemoglobin analyzers, the Biosen C-Line glucose and lactate analyzer, and the Quo-Test and Quo-Lab HbA1c Analyzers. They can also discover more about EKF Link, the company’s optional software platform designed to provide a flexible and secure method for connecting point-of-care devices to hospital and laboratory IT systems. Additionally, visitors can learn more about EKF Life Sciences, and the company’s latest developments in microbial fermentation, custom bioprocessing, and contract manufacturing.

EKF’s DiaSpect Tm is a hand-held analyzer that provides immediate hemoglobin results and hematocrit calculation while the Hemo Control hemoglobin analyzer delivers accurate hemoglobin and hematocrit results with one simple test. Similarly, the Biosen C-Line Line glucose and lactate analyzer from EKF is designed for lab-accurate glucose and lactate measurement in one test. Among other products on display at MEDICA 2023 is the revolutionary Quo-Lab semi-automated analyzer for HbA1c measurement that provides affordable A1c testing with results in just four minutes. The Quo-Test fully automated analyzer on display at MEDICA 2023 is designed for fast, accurate, and reliable HbA1c measurement with results available in only four minutes.

Related Links:
EKF Diagnostics 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Gold Member
Troponin T QC
Troponin T Quality Control
New
Treponema Pallidum Test
ZEUS IFA Fluorescent Treponemal Antibody-Absorption (FTA-ABS) Test System
New
Blood Culture Identification Panel
cobas ePlex BCID-GP Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.